Disease · MONDO_0016158

narcolepsy-cataplexy syndrome

6 sourcesdiseases-2026-09-18-0.1.0

Cite this record

ConductScience Library. narcolepsy-cataplexy syndrome. Diseases, record MONDO_0016158. Release diseases-2026-09-18-0.1.0, 18 Sept 2026. https://conductscience.org/library/diseases/MONDO_0016158

On this page

Disease

Names and IDs as Open Targets gives them. Its IDs in MeSH, Orphanet, the Disease Ontology and the NCI Thesaurus are those Open Targets states for it.

Name: narcolepsy-cataplexy syndrome; Open Targets
Open Targets ID: MONDO_0016158; Open Targets
Other names: Gelineau disease, Gelineau syndrome, Gelineau's Syndromes, Gelineau's syndrome, Gelineaus Syndrome, Gélineau disease, Narcolepsy (disorder), Narcolepsy NOS, Narcoleptic Syndrome, Narcoleptic Syndromes, Paroxysmal Sleep, Sleep, Paroxysmal, Syndrome, Gelineau, Syndrome, Gelineau's, Syndrome, Narcoleptic, Syndromes, Gelineau's, Syndromes, Narcoleptic, narcolepsy, narcolepsy cataplexy, narcolepsy type 1, narcolepsy with cataplexy, syndrome, narcolepsy cataplexy; Open Targets
Orphanet: ORPHA:2073; Orphanet
Highest stage of its drugs: Approval, for 10 of its 16 drugs, from DailyMed and FDA; Open Targets

Drugs16

The drugs Open Targets' clinical reports study for the disease, the highest stage first, then the most trial reports. The stage is Open Targets', the highest any of its sources reports for the pair, and each row names the sources that report it.

Drug	ChEMBL ID	Type	Open Targets' stage	Stage reported by	Reports	Of them trials	Trials shown here	Source
SODIUM OXYBATE	CHEMBL1200682	Small molecule	Approval	DailyMed	2	1	1	Drugs and targets
ARMODAFINIL	CHEMBL1201192	Small molecule	Approval	DailyMed	7	0	0	Drugs and targets
METHYLPHENIDATE	CHEMBL796	Small molecule	Approval	DailyMed	4	0	0	Drugs and targets
AMPHETAMINE SULFATE	CHEMBL501	Small molecule	Approval	DailyMed	3	0	0	Drugs and targets
PITOLISANT HYDROCHLORIDE	CHEMBL4164059	Small molecule	Approval	DailyMed and FDA	3	0	0	Drugs and targets
SOLRIAMFETOL HYDROCHLORIDE	CHEMBL4297212	Small molecule	Approval	DailyMed and FDA	2	0	0	Drugs and targets
DEXTROAMPHETAMINE	CHEMBL612	Small molecule	Approval	DailyMed	1	0	0	Drugs and targets
DEXTROAMPHETAMINE SACCHARATE	CHEMBL3989844	Small molecule	Approval	DailyMed	1	0	0	Drugs and targets
DEXTROAMPHETAMINE SULFATE	CHEMBL3544971	Small molecule	Approval	DailyMed	1	0	0	Drugs and targets
MODAFINIL	CHEMBL1373	Small molecule	Approval	DailyMed	1	0	0	Drugs and targets

1 to 10 of 16

See all 16 drugs

Targets9

The targets ChEMBL's mechanism records give for the disease's drugs, through Open Targets, the most drugs first. A mechanism record says what a drug acts on, not that the target causes the disease.

Target	Protein	Its drugs that act on it	Mechanisms	Highest stage of those drugs	Gene in Genes	Source
SLC6A3	Monoamine transporter	8	Dopamine transporter inhibitor; Dopamine transporter releasing agent; Monoamine transporter inhibitor	Approval	https://conductscience.org/library/genes/6531	Drugs and targets
SLC6A2	Monoamine transporter	6	Monoamine transporter inhibitor; Norepinephrine transporter inhibitor; Norepinephrine transporter releasing agent	Approval	https://conductscience.org/library/genes/6530	Drugs and targets
SLC18A2	Synaptic vesicular amine transporter	3	Synaptic vesicular amine transporter inhibitor	Approval	https://conductscience.org/library/genes/6571	Drugs and targets
HRH3	Histamine H3 receptor	2	Histamine H3 receptor inverse agonist	Approval	https://conductscience.org/library/genes/11255	Drugs and targets
GABBR1	GABA-B receptor	1	GABA-B receptor agonist	Approval	https://conductscience.org/library/genes/2550	Drugs and targets
GABBR2	GABA-B receptor	1	GABA-B receptor agonist	Approval	https://conductscience.org/library/genes/9568	Drugs and targets
HTR1A	5-hydroxytryptamine receptor 1A	1	Serotonin 1a (5-HT1a) receptor agonist	Phase 1	https://conductscience.org/library/genes/3350	Drugs and targets
SLC6A4	Monoamine transporter	1	Monoamine transporter inhibitor	Phase 3	https://conductscience.org/library/genes/6532	Drugs and targets
TAAR1	Trace amine-associated receptor 1	1	Trace amine-associated receptor 1 agonist	Phase 1	https://conductscience.org/library/genes/134864	Drugs and targets

Trials4

Trials an Open Targets clinical report links to the disease, posted results first, then the largest. A trial is shown when the release's checks confirm its link to the disease and Drugs and targets shows its link to one of the disease's drugs.

Trial	Title	Phase	Participants	Results first posted	Conditions	Drugs	Linked by	Source
NCT05687903	A Study of TAK-861 in Participants With Narcolepsy Type 1	Phase 2	112	2025-01-09	Narcolepsy Type 1	OVEPOREXTON	Its record names the disease	ClinicalTrials.gov
NCT05914194	A Eight-Week Study of NLS-2 (Mazindol Extended Release) in Participants With Narcolepsy Type 1	Phase 3	48		Narcolepsy Type 1, Narcolepsy With Cataplexy	MAZINDOL	Its record names the disease	ClinicalTrials.gov
NCT06809803	Extended-release Sodium Oxybate in Children	Phase 2	36		Narcolepsy Type 1 (NT 1)	SODIUM OXYBATE	Its record names the disease	ClinicalTrials.gov
NCT05015673	This is a Study to Determine the Effect of Multiple Doses of an Investigational Drug, Taken by Mouth, in People With Narcolepsy-cataplexy. Accepting Both Males and Females Ages of 18 Years to 55 Years. This Study Will be Conducted in the US and Will Require Approximately 13 Weeks Participation.	Phase 1	18		Narcolepsy	ULOTARONT	Its record names the disease	ClinicalTrials.gov

Comparisons in its trials0

Comparisons Trial comparisons calculated in the trials shown here, most participants first. A comparison in one of these trials does not always compare a treatment for the disease, so read the two groups.

None in this release.

Papers from its trials3

The papers the trials shown here list on ClinicalTrials.gov as their results (RESULT) or as drawn from them (DERIVED), results first, newest first.

PMID	Listed as	Trials listing it	Source
41359331	DERIVED	1	PubMed
40367374	DERIVED	1	PubMed
37209427	DERIVED	1	PubMed

Data dates

The date of each source this release read.

Open Targets: 2026-09-18; Open Targets
Drug links and their checks, from Drugs and targets: 2026-09-18; Drugs and targets
ClinicalTrials.gov, from Trials: 2026-11-12; Trials
Comparisons, from Trial comparisons: 2026-03-23; Trial comparisons
PubMed, for the checks: 2026-11-06; PubMed
MeSH, for the checks: 2026-11-10; MeSH

Sources 6

ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
ChEMBL, through Open TargetsCC BY-SA 3.0
ClinicalTrials.govNo license stated
NLM's MeSHNLM's terms
Open TargetsCC0 1.0
PubMedNLM's terms

Each source's terms

ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
ClinicalTrials.govnone stated
NLM's MeSHNLM's
Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
PubMedNLM's terms

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this disease from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/diseases/v1/MONDO_0016158

GET https://conductscience.org/api/diseases/v1/MONDO_0016158/drugs

API reference For AI assistants